A citation-based method for searching scientific literature

Lei Ding, Conny A Gysemans, Geert Stangé, Yves Heremans, Yixing Yuchi, Tatiana Takiishi, Hannelie Korf, Marie Chintinne, Richard D Carr, Harry Heimberg, Daniel Pipeleers, Chantal Mathieu. PLoS One 2014
Times Cited: 15







List of co-cited articles
65 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
84
46

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
73
40

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).
Takuya Awata, Akira Shimada, Taro Maruyama, Yoichi Oikawa, Nobuyuki Yasukawa, Susumu Kurihara, Yumi Miyashita, Masako Hatano, Yuichi Ikegami, Masafumi Matsuda,[...]. Diabetes Ther 2017
24
40

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
36
33

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Jae Min Cho, Hye Won Jang, Hwanju Cheon, Yeon Taek Jeong, Do-Hoon Kim, Yu-Mi Lim, Song-Hyen Choi, Eun-Kyoung Yang, Chang-Yell Shin, Moon Ho Son,[...]. Diabetes Res Clin Pract 2011
40
26

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
271
26



Type 1 Diabetes Prevention in NOD Mice by Targeting DPPIV/CD26 Is Associated with Changes in CD8⁺T Effector Memory Subset.
Núria Alonso, María Teresa Julián, Jorge Carrascal, Roger Colobran, Irma Pujol-Autonell, Silvia Rodriguez-Fernández, Aina Teniente, Marco Antonio Fernández, Antoni Miñarro, María Carmen Ruiz de Villa,[...]. PLoS One 2015
7
57

Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
Marcelo Maia Pinheiro, Caroline Lais Stoppa, Claudete Justina Valduga, Cristina Eunice Okuyama, Renata Gorjão, Regina Mara Silva Pereira, Susana Nogueira Diniz. Eur J Pharm Sci 2017
39
26

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.
L Chatenoud, E Thervet, J Primo, J F Bach. Proc Natl Acad Sci U S A 1994
497
20

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil M Jain, Jack Wahlen, Robert J Ferry, Bruce Bode, Stephen Aronoff, Christopher Holland, David Carlin,[...]. Lancet 2011
290
20

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
B Keymeulen, M Walter, C Mathieu, L Kaufman, F Gorus, R Hilbrands, E Vandemeulebroucke, U Van de Velde, L Crenier, C De Block,[...]. Diabetologia 2010
211
20

Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo.
A Steinbrecher, D Reinhold, L Quigley, A Gado, N Tresser, L Izikson, I Born, J Faust, K Neubert, R Martin,[...]. J Immunol 2001
124
20

CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently.
C Klemann, J Schade, R Pabst, S Leitner, J Stiller, S von Hörsten, M Stephan. Clin Exp Immunol 2009
29
20



Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes.
Tímea Varga, Anikó Somogyi, Gábor Barna, Barna Wichmann, Géza Nagy, Károly Rácz, László Selmeci, Gábor Firneisz. Pathol Oncol Res 2011
39
20

Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones.
D Reinhold, B Hemmer, B Gran, I Born, J Faust, K Neubert, H F McFarland, R Martin, S Ansorge. J Neuroimmunol 1998
48
20


Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
89
20

One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin.
Marcos M Lima-Martínez, Ernesto Guerra-Alcalá, Miguel Contreras, José Nastasi, Janelle A Noble, Constantin Polychronakos. Endocrinol Diabetes Metab Case Rep 2014
12
25

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Qixian Wang, Min Long, Hua Qu, Rufei Shen, Rui Zhang, Jing Xu, Xin Xiong, Hui Wang, Hongting Zheng. J Diabetes Res 2018
19
20

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
Ryo Kodera, Kenichi Shikata, Tetsuharu Takatsuka, Kaori Oda, Satoshi Miyamoto, Nobuo Kajitani, Daisho Hirota, Tetsuichiro Ono, Hitomi Kataoka Usui, Hirofumi Makino. Biochem Biophys Res Commun 2014
66
20

Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.
Song Xue, Clive Wasserfall, Matthew Parker, Sean McGrail, Kieran McGrail, Martha Campbell-Thompson, Desmond A Schatz, Mark A Atkinson, Michael J Haller. J Diabetes Complications 2010
17
13

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
Lucy Mastrandrea, Jihnhee Yu, Torsten Behrens, John Buchlis, Christine Albini, Shannon Fourtner, Teresa Quattrin. Diabetes Care 2009
142
13

CD3-specific antibodies: a portal to the treatment of autoimmunity.
Lucienne Chatenoud, Jeffrey A Bluestone. Nat Rev Immunol 2007
258
13

Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.
Vitaly Ablamunits, Octavian Henegariu, Jakob Bondo Hansen, Lynn Opare-Addo, Paula Preston-Hurlburt, Pere Santamaria, Thomas Mandrup-Poulsen, Kevan C Herold. Diabetes 2012
88
13

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Kevan C Herold, William Hagopian, Julie A Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E Gitelman, David M Harlan, Danlin Xu, Robert A Zivin,[...]. N Engl J Med 2002
835
13

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon,[...]. N Engl J Med 2005
784
13


Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function.
Kei Ohnuma, Nam H Dang, Chikao Morimoto. Trends Immunol 2008
162
13


The multifunctional or moonlighting protein CD26/DPPIV.
Emil Boonacker, Cornelis J F Van Noorden. Eur J Cell Biol 2003
233
13

CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus.
Sang Ah Lee, Young Ree Kim, Eun Jin Yang, Eun-Jeong Kwon, Sun Hyung Kim, Sung Ha Kang, Doek Bae Park, Byung-Chul Oh, Jinseok Kim, Sang Taek Heo,[...]. J Clin Endocrinol Metab 2013
80
13

Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions.
Aliza Biton, Siegfried Ansorge, Ute Bank, Michael Täger, Dirk Reinhold, Stefan Brocke. Immunobiology 2011
8
25


Sitagliptin exerts an antinflammatory action.
Antoine Makdissi, Husam Ghanim, Mehul Vora, Kelly Green, Sanaa Abuaysheh, Ajay Chaudhuri, Sandeep Dhindsa, Paresh Dandona. J Clin Endocrinol Metab 2012
171
13

CD8+ T cells in type 1 diabetes.
Sue Tsai, Afshin Shameli, Pere Santamaria. Adv Immunol 2008
80
13

The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Yunjuan Zhao, Lin Yang, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2014
39
13

Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency.
Song Xue, Clive H Wasserfall, Matthew Parker, Todd M Brusko, Sean McGrail, Kieran McGrail, Marcus Moore, Martha Campbell-Thompson, Desmond A Schatz, Mark A Atkinson,[...]. Ann N Y Acad Sci 2008
24
13

Exendin-4 modulates diabetes onset in nonobese diabetic mice.
Irene Hadjiyanni, Laurie L Baggio, Philippe Poussier, Daniel J Drucker. Endocrinology 2008
79
13



CD26/DPPIV inhibition alters the expression of immune response-related genes in the thymi of NOD mice.
María Teresa Julián, Núria Alonso, Roger Colobran, Alex Sánchez, Antoni Miñarro, Irma Pujol-Autonell, Jorge Carrascal, Silvia Rodríguez-Fernández, Rosa María Ampudia, Marta Vives-Pi,[...]. Mol Cell Endocrinol 2016
6
33

Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Andreia Gonçalves, Catarina Marques, Ermelindo Leal, Carlos F Ribeiro, Flávio Reis, António F Ambrósio, Rosa Fernandes. Biochim Biophys Acta 2014
54
13

Vildagliptin induces β-cell neogenesis and improves the lipid profile in a later phase of type 1 diabetes.
Pedro H de Amorim Miranda, Otávio M Monteiro, Joamyr V Rossoni, Marcelo E Silva, Wanderson G de Lima, Daniela C Costa. Curr Pharm Biotechnol 2015
6
33

Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.
J E Schopman, J B L Hoekstra, B M Frier, M T Ackermans, J J J de Sonnaville, A M Stades, R Zwertbroek, B Hartmann, J J Holst, F K Knop,[...]. Diabetes Obes Metab 2015
13
15

C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Odd Erik Johansen, Bernhard O Boehm, Valdemar Grill, Peter A Torjesen, Sudipta Bhattacharya, Sanjay Patel, Kristiane Wetzel, Hans-Juergen Woerle. Diabetes Care 2014
42
13

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
66
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.